There were no non-cash financing activities for the periods presented.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
1. |
BASIS OF PRESENTATION AND BUSINESS |
Oculus VisionTech, Inc. (the "Company") is a development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Substantially all of the Company's assets and substantially all its operations are located and conducted in the United States and Canada.
The unaudited condensed consolidated financial statements and notes herein should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the roles and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the SEC’s rules and regulations. Although management believes that the disclosures are adequate and make the information presented not misleading. In the opinion of management, all adjustments, which are of a normal and recurring nature (except as otherwise noted), that are necessary to present fairly the Company’s financial position as of March 31, 2023 and December 31, 2022, and its results of operation for the three months ended March 31, 2023 and 2022, and cash flows for the three months ended March 31, 2023 and 2022
These condensed interim consolidated financial statements are prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception and does not currently have the financial resources to sustain operations in the long-term. As shown in the financial statements, the Company has incurred a loss of $235,059 for the three months ended March 31, 2023 and, in addition the Company incurred losses of $1,649,589 for the year ended December 31, 2022. As of March 31, 2023, the Company had an accumulated deficit of $48,030,493 and working capital of $215,373. As a result of the Company’s current financial position and challenging access to capital, there can be no assurance that the Company will be able raise additional funds in the future, in which case the Company will be unable to meet its financial obligations. These material uncertainties raise substantial doubt upon the Company’s ability to continue as a going concern. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations as they come due which management believes it will be able to do. To date, the Company has funded operations primarily through the issuance of common stock and warrants to outside investors and the Company’s management. The Company believes that its operations will generate additional funds and that additional funding from outside investors and the Company’s management will continue to be available to the Company when needed.
There are many external factors that can adversely affect general workforces, economies and financial markets globally. Examples include, but are not limited to, the COVID-19 global pandemic and political conflict in other regions. It is not possible for the Company to predict the duration or magnitude of adverse results of such external factors and their effect on the Company’s business or ability to raise funds.
3. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Basis of consolidation
These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On May 9, 2023, the Board approved the condensed interim consolidated financial statements dated March 31, 2023.
These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.
Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.
10
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
The controlled entities are listed in the following table:
Name of Subsidiary | Country of Incorporation | | Ownership Interest at March 31, 2023 | | | Ownership Interest at December 31, 2022 | | Principal Activity |
| | | | | | | | | | |
ComplyTrust Inc. | US/Delaware | | | 100 | % | | | 100 | % | Software Development |
Significant judgments, estimates and assumptions
The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.
The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:
Significant judgments
| ● | the determination of functional currencies |
| ● | share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information. |
Cash and cash equivalents
Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.
Impairment of long-lived assets and long-lived assets to be disposed of
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.
Research and development
Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at March 31, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.
11
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
Intangible asset
Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.
The useful lives of intangible assets are assessed as either finite or indefinite.
Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.
Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.
Income taxes
The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.
Net loss per share
Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended March 31, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 5,415,000 ( December 31, 2022: 5,415,000) stock options and 17,400,000 ( December 31, 2022: 17,400,000) warrants were excluded from the calculation.
Right of use asset
The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove or to restore the underlying asset or the site on which it is located, less any lease incentives received.
The right of use assets are subsequently amortized from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term using the straight line method.
12
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
Lease liability
The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.
Lease payments included in the measurement of the lease liability comprise the following payments during the lease term: fixed payments (including in-substance fixed payments), and the exercise price under a purchase option that the Company is reasonably certain to exercise.
The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising mainly if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option, or if there is a revised in substance fixed lease payment.
When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use asset, or is recorded in profit or loss if the carrying amount of the right of use asset has been reduced to zero.
Stock-based compensation
The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.
The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.
Functional currency
The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.
In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.
Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.
13
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
Recently issued accounting pronouncements
The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.
4. |
PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid expenses and other current assets consist of the following:
|
|
March 31, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Prepaid expenses |
|
$ |
12,076 |
|
|
$ |
28,028 |
|
Tax Receivable – Canadian GST |
|
|
1,652 |
|
|
|
2,210 |
|
|
|
$ |
13,728 |
|
|
$ |
30,238 |
|
5. |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES |
Accounts payable and accrued expenses consist of the following:
| | March 31, 2023 | | | December 31, 2022 | |
| | | | | | | | |
Accounts payable | | $ | 265,114 | | | $ | 224,716 | |
Accrued fees and expenses | | | 37,092 | | | | 51,869 | |
| | $ | 302,206 | | | $ | 276,585 | |
The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on March 31, 2023 and December 31, 2022.
The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.
As of March 31, 2023, there were 1,875,000 common shares held in escrow.
14
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
During the period ended March 31, 2023 and year ended December 31, 2022, the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares may be reserved for granting of stock options. All of the options granted vest 20% every six months.
However, all options will be considered vested if one of the following criteria are met by the Company:
| i. | Meeting sales forecasts: |
| | | |
| | - | The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary. |
| ii. | the listing of the Company on any national securities exchange. |
| iii. | a Change of Control Event. |
During the period ended March 31, 2023, the Company did not grant any stock options and recorded $36,174 share-based compensation for vested portion that were previously granted.
The changes in options are as follows:
| | Number of options | | | Weighted average exercise price | | | Aggregate Intrinsic Value | |
Options outstanding, December 31, 2021 | | | 5,315,000 | | | $ | 0.49 | | | $ | - | |
Granted | | | 100,000 | | | | 0.80 | | | | - | |
Options outstanding, December 31, 2022 and March 31, 2023 | | | 5,415,000 | | | $ | 0.50 | | | $ | - | |
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at March 31, 2023.
Details of options outstanding as at March 31, 2023 are as follows:
Exercise price (CAD) | | | Number of options outstanding | | Expiry date | | Number of options exercisable | | | Remaining contractual life (years) | |
| | | | | | | | | | | | | | | |
| $0.350 | | | | 3,600,000 | | July 21, 2023 | | | 3,600,000 | | | | 0.31 | |
| $0.450 | | | | 250,000 | | December 21, 2023 | | | 200,000 | | | | 0.73 | |
| $1.200 | | | | 500,000 | | January 29, 2024 | | | 400,000 | | | | 0.83 | |
| $0.800 | | | | 375,000 | | June 10, 2024 | | | 225,000 | | | | 1.20 | |
| $0.600 | | | | 590,000 | | October 14, 2024 | | | 236,000 | | | | 1.54 | |
| $0.800 | | | | 100,000 | | January 31, 2025 | | | 40,000 | | | | 1.84 | |
| | | | | | | | | | | | | | | |
| | | | | 5,415,000 | | | | | 4,701,000 | | | | | |
15
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
The changes in warrants are as follows:
|
|
Number of warrants |
|
|
Weighted average exercise price |
|
Warrants outstanding, December 31, 2021, December 31, 2022 and March 31, 2023 |
|
|
17,400,000 |
|
|
$ |
0.28 |
|
Details of warrants outstanding as at March 31, 2023 are as follows:
Exercise price | | | | Number of warrants outstanding | | Expiry date | | Number of warrants exercisable | | | Remaining contractual life (years) | |
| | | | | | | | | | | | | | | | |
$ | 1.00 | | (CAD) | | | 4,900,000 | | April 19, 2023(2) | | | 4,900,000 | | | | 0.05 | |
$ | 0.001 | (1) | (USA) | | | 12,500,000 | | June 4, 2025 | | | - | | | | 2.18 | |
| | | | | | | | | | | | | | | | |
| | | | | | 17,400,000 | | | | | 4,900,000 | | | | | |
|
(1) |
No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per CTI’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control. |
|
(2) |
Expired subsequent to March 31, 2023 |
9. | SELLING, GENERAL AND ADMINISTRATIVE |
The breakdown of selling, general and administrative for the period ended March 31, 2023 and 2022 is as follows:
| | | | | | |
| | 2023 | | | 2022 | |
| | | | | | | | |
Filing and regulatory fees | | $ | 12,577 | | | $ | 22,447 | |
Marketing | | | - | | | | 37,965 | |
Professional fees | | | 14,091 | | | | 6,225 | |
Rent | | | 10,813 | | | | 9,381 | |
Office and administration | | | 35,296 | | | | 20,235 | |
| | | | | | | | |
| | $ | 72,777 | | | $ | 96,253 | |
16
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
10. |
RESEARCH AND DEVELOPMENT |
The breakdown of research and development for the period ended March 31, 2023 and 2022 is as follows:
|
|
|
|
|
|
|
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Project management |
|
$ |
84,203 |
|
|
$ |
11,990 |
|
Software development |
|
|
49,765 |
|
|
|
269,250 |
|
Business development |
|
|
3,952 |
|
|
|
32,451 |
|
Payroll |
|
|
30,486 |
|
|
|
31,772 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
84,203 |
|
|
$ |
345,463 |
|
Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.
The Company defines its key management as the Board of Directors, Chief Executive Officer, President, and Chief Financial Officer. Remuneration of directors and key management personnel of the Company for the period ended March 31, 2023 and 2022 was as follows:
|
|
|
|
|
|
|
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Consulting |
|
$ |
45,000 |
|
|
$ |
- |
|
Selling general and administrative |
|
|
15,369 |
|
|
|
27,493 |
|
Share-based compensation to directors and officers |
|
|
1,442 |
|
|
|
17,431 |
|
|
|
$ |
61,811 |
|
|
$ |
44,924 |
|
The Company for the period ended March 31, 2023 and 2022 reimbursed a related party $15,369 and $27,493, respectively, for selling, general and administrative expenses paid on behalf of the Company. The Company also recorded share-based compensation of $1,442 (2022 - $17,431) for options vested to related parties during the period ended March 31, 2023 and 2022.
12. | FINANCIAL INSTRUMENTS AND RISKS |
Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are described below.
Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).
17
OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022 and 2021
(Stated in US Dollars)
Fair value of financial instruments
The Company has various financial instruments including cash and cash equivalents, accounts payable and accrued expenses, and accounts payable and accrued expenses – related parties. The carrying values of accounts payable and accrued expenses and accounts payable and accrued expenses – related parties approximate their fair values due to the short-term nature of these financial instruments.
Cash and cash equivalents is carried at a level 1 fair value measurement.
The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:
Credit risk
The Company is exposed to credit risk only with respect to uncertainties as to timing and amount of collectability of receivables. The Company believes its credit risk is low because receivables is comprised of goods and services tax (GST) which is recoverable from the governing body in Canada. Management does not believe the receivables are impaired. The Company doesn’t believe there is significant credit risk associated with cash as these amounts are held with major Canadian banks.
Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at March 31, 2023, the Company had a cash and cash equivalents balance of $529,692 ( December 31, 2022 – $687,602) to settle current liabilities of $328,047 ( December 31, 2022 – $302,423). All of the Company’s financial liabilities have contractual maturities of 30 days or due on demand and are subject to normal trade terms.
Interest rate risk
Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize such a loss is limited as it does not have any significant interest-bearing financial instruments.
Foreign currency risk
As at March 31, 2023 and December 31, 2022, the Company is exposed to foreign currency risk as certain monetary financial instruments are denominated in Canadian currency. The Company’s sensitivity analysis suggests that reasonably expected changes in the rates of exchange in the United States would change foreign exchange gain or loss by an insignificant amount.
The Company has one operating lease with unrelated third parties for office space at Vancouver, Canada.
The lease at the Vancouver, Canada location is on a month-to-month basis with monthly rental payments of $3,950 (CND). For the period ended March 31, 2023 and 2022 rent expense was $10,305 and $8,874, respectively.
14. |
SEGMENTED INFORMATION |
The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and United States.
18